proPSMA
Proved PSMA PET is far more accurate than conventional scans for staging, with less radiation.
Overview
proPSMA, registered as ANZCTR12617000005358, sponsored by Peter MacCallum Cancer Centre and ANZUP and reported in the Lancet in 2020, proved that PSMA PET/CT is far more accurate than CT plus bone scan for staging high-risk localised prostate cancer, with less radiation. It randomised 302 men, found an accuracy of 92 percent for PSMA PET against 65 percent for conventional imaging, produced fewer equivocal findings and changed management more often. Nuclide links it to PSMA PET, Peter MacCallum, ANZUP, Michael Hofman, Ian Davis and Declan G. Murphy, and its findings are consistent with the OSPREY and CONDOR studies for the fluorine-18 tracer DCFPyL. Whether better staging translates into better outcomes, rather than only different decisions, is the open question that follows any diagnostic accuracy trial. PSMA PET has its own page.
- 92 vs 65 out of 100 reached this endpoint with PSMA PET/CT compared with CT + bone scan; 27 more per 100.
- Roughly one extra person helped for every 4 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- The p-value (<0.0001) says a difference this large would rarely happen by chance; it does not say how large or how useful the difference is.
- This endpoint is not one of the standard survival or response measures; read it alongside the trial's primary result.
- These results apply to the people the trial enrolled: High-risk localised prostate cancer staging: PSMA PET/CT vs CT + bone scan. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (PSMA); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
302 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Accuracy for pelvic nodal or distant metastases (AUC)primary | PSMA PET/CT | 150 | 92% | - | <0.0001 | link |
| CT + bone scan | 152 | 65% |
Similar pages
not linked directly; found by shared links- TrialTheraP (ANZUP 1603)
Shares ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, Michael Hofman, PSMA PET.
- TermBiochemical recurrence (BCR)
Shares Localised prostate cancer, high and very high risk, PSMA PET, Fluorine-18, Prostate cancer.
- TrialOSPREY
Shares Localised prostate cancer, high and very high risk, PSMA PET, Fluorine-18.
- TrialDiagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
Shares Localised prostate cancer, high and very high risk, Fluorine-18, Prostate cancer.
- TrialLIGHTHOUSE
Shares Localised prostate cancer, high and very high risk, PSMA PET, Fluorine-18.
- PersonShahneen Sandhu
Shares ANZUP Cancer Trials Group, Peter MacCallum Cancer Centre, Prostate cancer.
- JournalEuropean Urology
Shares Declan G. Murphy, Prostate cancer.
- AgentCholine C-11
Shares PSMA PET, Fluorine-18, Prostate cancer.